[Jackie07]

Here's the 'requested' abstract (I'm very scatter-brained and easily side-tracted...):

Clin Cases Miner Bone Metab. 2012 May;9(2):89-91. Epub 2012 Sep 30.
Osteoporosis and aromatase inhibitors: experience and future prospects.

Bosco D.
Source

UOSD of Endocrinology, AO San Giovanni Addolorata, Rome, Italy.

Abstract

INTRODUCTION:

The aim of this study is to improve the assistance given to patients under treatment with aromatase inhibitors in order to prevent secondary osteoporosis through the planning of an awareness programme for the oncologist and offering a facilitated treatment path.
MATERIALS AND METHODS:

Thirty-nine postmenopausal women treated with aromatase inhibitors for breast cancer were selected. For each subject, the age at the beginning of the therapy, the type of aromatase inhibitors and the age at the performance of the bone densitometry was registered. In addition, the use of osteoporosis medication and supplementation of calcium and vitamin D were evaluated. Participants were required to answer a questionnaire consisting of closed questions relating to booking procedures of the bone densitometry and about their own knowledge of osteoporosis related to the use of aromatase inhibitors.
CONCLUSIONS:

Although there is evidence of negative impact of the aromatase inhibitors on bone, our data still show a poor application of the recommendations in order to prevent osteoporosis related to the administration of these drugs. Our suggestion is a more active implementation of the guidelines, also by means of a greater collaboration between the oncologist and the specialist in osteoporosis, and the offer of a diagnostic and therapeutic pathway.

PMID:23087717[PubMed] PMCID:PMC3476523Free PMC Article


Images from this publication.See all images (5) Free text
Figure 1
Questionnaire relating to booking procedures of the bone mineral densitometry and about the women’s knowledge of osteoporosis related to the use of aromatase inhibitors.

Osteoporosis and aromatase inhibitors: experience and future prospects
Clin Cases Miner Bone Metab. 2012 May-Aug;9(2):89-91.



Figure 2
Numbers of subjects who performed the bone mineral densitometry depending on when aromatase inhibitors were initiated.

Osteoporosis and aromatase inhibitors: experience and future prospects
Clin Cases Miner Bone Metab. 2012 May-Aug;9(2):89-91.



Figure 3
Results of bone mineral densitometry in the subgroups of patients divided by the timing of the performance of the radiological exam.

Osteoporosis and aromatase inhibitors: experience and future prospects
Clin Cases Miner Bone Metab. 2012 May-Aug;9(2):89-91.



Figure 4
Subjects who recommended the bone mineral densitometry.

Osteoporosis and aromatase inhibitors: experience and future prospects
Clin Cases Miner Bone Metab. 2012 May-Aug;9(2):89-91.